Mary S. Holubasch

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

Tim West, Kristopher M. Kirmess, Matthew R. Meyer et al. · Molecular Neurodegeneration · 2021 · 220 citations · Full text

The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis

Kristopher M. Kirmess, Matthew R. Meyer, Mary S. Holubasch et al. · Clinica Chimica Acta · 2021 · 129 citations · Full text

Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment

Yan Hu, Kristopher M. Kirmess, Matthew R. Meyer et al. · JAMA Network Open · 2022 · 125 citations · Full text

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

Matthew R. Meyer, Kristopher M. Kirmess, Stephanie Eastwood et al. · Alzheimer s & Dementia · 2024 · 92 citations · Full text

The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey

Heidi A. Schoenfeld, Tim West, Philip B. Verghese et al. · Toxicology and Applied Pharmacology · 2017 · 44 citations · Full text